Armour Thyroid vs Tirosint: What to Do When One Fails

Why This Comparison Matters More for Women Than for Men

Thyroid disease is heavily female. Women are five to eight times more likely than men to develop hypothyroidism, and they carry that diagnosis through decades of hormonal change: puberty, the menstrual cycle, pregnancy, postpartum, perimenopause, and post-menopause. Each of those stages can shift how well your current thyroid medication works, which explains why a dose or formulation that felt perfect at 32 may feel completely wrong at 47.

Armour Thyroid and Tirosint occupy opposite ends of the thyroid-replacement spectrum. Armour gives you both thyroid hormones in one tablet. Tirosint gives you a single, highly absorbable form of T4, letting your own body convert what it needs to T3. Neither is universally superior. The right choice depends on your absorption, your hormonal environment, your life stage, and very specifically, why your current therapy is failing.

What "Failure" Actually Looks Like

"Failure" is not the same as a mildly off TSH. These are the failure patterns that actually justify a switch:

• TSH normalized but symptoms (fatigue, brain fog, hair loss, cold intolerance, weight gain) persist after at least 6 weeks at a stable dose
• Dose requirements keep climbing with no clear physiologic explanation
• Persistent absorption problems: celiac disease, Hashimoto's gastritis, bariatric surgery, or proton-pump inhibitor use
• Intolerance to fillers or dyes in standard levothyroxine tablets
• Free T3 in the low-normal range despite adequate T4 dosing, suggesting poor peripheral conversion

Armour Thyroid: What It Is and Who It Helps

Armour Thyroid is desiccated porcine thyroid gland, standardized to contain 38 mcg T4 and 9 mcg T3 per grain (60 mg). That fixed 4:1 T4:T3 ratio is structurally different from the roughly 20:1 ratio found in healthy human thyroid secretion, which means the T3 pulse from each dose is relatively high and short-lived.

Why Some Women Do Better on NDT

The 2013 Hoang et al. Crossover trial published in JCEM randomized 70 patients to NDT versus levothyroxine for one year each. Forty-nine percent preferred NDT, and those patients lost an average of 4 pounds more on NDT than on levothyroxine. Cognitive symptoms improved more on NDT in a subset of participants. This is one of the most-cited head-to-head datasets in this space, and it matters because it was a crossover design, so patients served as their own controls.

For women, poor T4-to-T3 conversion is a recurring clinical problem. Estrogen itself does not directly impair conversion, but chronic low-grade inflammation (common in autoimmune thyroid disease), caloric restriction, and high cortisol (which rises during perimenopause and postpartum) all suppress deiodinase activity. Women who have those drivers and feel unwell despite normal T4 levels may do better with a medication that delivers T3 directly.

Armour's Limitations

The fixed T4:T3 ratio is also Armour's main weakness. You cannot adjust the T3 dose independently. Postmenopausal women and women with cardiovascular risk factors may not tolerate the T3 pulse well, since T3 has a shorter half-life (roughly 1 day vs. 7 days for T4) and can cause palpitations, anxiety, and raised heart rate if levels spike. Armour is also not recommended as first-line therapy during pregnancy by current ATA/ACOG guidance, and dose-to-dose consistency across lots, while tighter than it used to be, is still somewhat less precise than synthetic options.

Tirosint: What It Is and Who It Helps

Tirosint is a brand-name levothyroxine gel capsule containing only levothyroxine sodium, glycerin, gelatin, and water. No lactose. No acacia. No dyes. The liquid formulation bypasses the dissolution step that standard levothyroxine tablets require before absorption can begin.

The Absorption Advantage

This matters far more than it sounds. Standard levothyroxine tablets require stomach acid for dissolution. Women with hypothyroid-associated hypochlorhydria, Hashimoto's-related gastritis, small intestinal bacterial overgrowth (SIBO), celiac disease, or who take proton-pump inhibitors regularly often absorb standard tablets poorly and unpredictably.

The Vita et al. 2014 study in Endocrine compared Tirosint gel capsules to standard levothyroxine tablets in patients with absorption problems and found that Tirosint produced significantly lower and more stable TSH values on the same or lower doses, with better biochemical control. Patients on the gel capsule required approximately 22% less levothyroxine to achieve equivalent TSH suppression, which is a clinically meaningful difference when you are trying to avoid overtreatment.

Who Benefits Most from Tirosint

• Women with confirmed celiac disease or Hashimoto's gastritis
• Women after bariatric surgery, particularly Roux-en-Y gastric bypass
• Women with SIBO or chronic proton-pump inhibitor use
• Women with allergies or sensitivities to lactose, acacia, or synthetic dyes in standard tablets
• Women whose TSH fluctuates erratically despite consistent tablet-dose timing

Tirosint is T4 only, so the benefit depends on adequate peripheral T4-to-T3 conversion. If your failure mode is poor conversion rather than poor absorption, Tirosint will not solve the problem.

Head-to-Head: How the Two Drugs Compare Across Women's Life Stages

Reproductive Years (Ages 18-40)

During reproductive years, your thyroid hormone requirements can shift across the menstrual cycle. Estrogen raises thyroid-binding globulin (TBG), which binds T4 in circulation and can reduce free T4 availability. Women on oral contraceptives, who have persistently high estrogen, often need dose increases of both NDT and levothyroxine. Neither Armour nor Tirosint has a pharmacokinetic advantage here over the other, but dose tracking across cycle phases is worth discussing with your clinician if you are having cyclical symptoms.

Trying to Conceive and Early Pregnancy

This is the life stage where the choice between Armour and Tirosint becomes most consequential. The American Thyroid Association and ACOG both recommend maintaining TSH below 2.5 mIU/L before conception and below 2.5-3.0 mIU/L in the first trimester. Levothyroxine (T4) is the recommended standard of care in pregnancy because T3 crosses the placenta less efficiently than T4, and the fetal thyroid depends partly on maternal T4 for its own T3 production.

NDT's T3 component does not provide reliable transplacental T4 transfer for fetal brain development in the same way that pure T4 does. For this reason, most endocrinologists and OB-GYNs recommend switching women on Armour to a pure T4 formulation before conception or as soon as pregnancy is confirmed. Tirosint, as a pure T4 gel capsule, fits this clinical need well and is particularly useful for pregnant women whose gut absorption is compromised by pregnancy-related nausea, hyperemesis, or concurrent GI conditions.

Thyroid requirements typically increase by 30-50% during pregnancy, and the dose increase is usually needed by weeks 4-6. Women planning pregnancy should alert their clinician at the point of trying to conceive, not after a positive test.

Postpartum and Lactation

Postpartum thyroiditis affects approximately 5-10% of women in the year after delivery and may cause a transient hyperthyroid phase followed by hypothyroidism. Levothyroxine, including Tirosint, is considered safe during breastfeeding. Thyroid hormone is present in breast milk in small amounts, but the amount transferred from a therapeutic dose is not considered clinically significant for the infant. NDT is generally also considered compatible with breastfeeding, though specific lactation data for the NDT formulation is thinner than for levothyroxine.

After delivery, women who were on Armour pre-pregnancy and switched to Tirosint for the pregnancy may choose to continue Tirosint postpartum or switch back, depending on symptom response.

Perimenopause (Ages 40-55, Variable)

Perimenopause is when thyroid replacement therapy most commonly stops working at a previously stable dose. Estrogen fluctuations alter TBG, FSH and LH surges have no direct thyroid effect but the associated sleep disruption and cortisol changes can suppress T4-to-T3 conversion. Symptoms of perimenopause (fatigue, brain fog, weight gain, mood changes) overlap almost completely with hypothyroid symptoms, making this the most diagnostically confusing life stage for thyroid management.

The WomanRx Perimenopause Thyroid Failure Framework: When a previously well-controlled woman in her 40s or early 50s starts feeling hypothyroid again, consider these drivers in order before simply raising the dose:

1. TBG increase from fluctuating estrogen (check free T4, not just TSH)
2. Worsening gut absorption from age-related hypochlorhydria (consider switch to Tirosint)
3. Reduced peripheral conversion from elevated cortisol (check free T3; consider adding T3 or switching to NDT)
4. New or worsening autoimmune disease activity (check TPO antibodies, anti-TG)
5. Drug-nutrient interaction with new supplements (calcium, iron, biotin all interfere with levothyroxine absorption)

If the failure mode is absorption, Tirosint is the cleaner switch. If the failure mode is poor conversion, Armour or the addition of a small liothyronine dose is more rational.

Post-Menopause

After menopause, estrogen drops and TBG declines, which can actually improve free T4 availability. Women who needed dose increases during the perimenopause transition sometimes need modest reductions post-menopause. Bone density becomes a priority concern: excess thyroid hormone, particularly excess T3, suppresses bone mineral density by accelerating bone turnover. Post-menopausal women on NDT should have bone density monitored annually and keep TSH in the low-normal range (0.5-1.5 mIU/L) rather than suppressed.

Women on hormone therapy (HT) for menopause who are also on levothyroxine typically need dose increases because oral estrogen raises TBG. Transdermal estrogen has a smaller effect on TBG and may not require a levothyroxine dose change. This interaction applies equally to Tirosint and Armour.

Pregnancy and Lactation Safety

Pregnancy: Levothyroxine (T4) is the standard of care for hypothyroidism in pregnancy. Tirosint, as a pure T4 preparation, aligns with this recommendation. Armour Thyroid is not recommended as first-line therapy during pregnancy. The T3 component of Armour has limited placental transfer and does not substitute for the T4 the fetus needs for brain development. If you are currently taking Armour and become pregnant, speak with your clinician immediately about transitioning to a T4-only formulation. The dose conversion is 1 grain (60 mg) of Armour Thyroid to approximately 100 mcg of levothyroxine, but individual adjustment based on TSH is always required.

TSH should be checked every 4 weeks in the first half of pregnancy and at least once in the second half, per ATA pregnancy guidelines.

Lactation: Both levothyroxine and desiccated thyroid are considered compatible with breastfeeding. Thyroid hormones are present in breast milk in physiologic amounts, and therapeutic doses do not deliver supraphysiologic levels to the infant. Continue your thyroid medication while breastfeeding; do not stop without medical guidance.

Contraception note: Neither Armour Thyroid nor Tirosint is a teratogen, but uncontrolled hypothyroidism itself raises miscarriage and stillbirth risk. If you are not planning pregnancy and are of reproductive age, reliable contraception is important not because of the drug but because of the underlying condition. Hormonal contraceptives, particularly combined oral contraceptives, will raise TBG and may require a thyroid dose adjustment within 3 months of starting them.

Conditions Where One Drug Has a Clear Edge

Hashimoto's Thyroiditis

Hashimoto's is the leading cause of hypothyroidism in women, affecting an estimated 14 million Americans, most of them women. The autoimmune component means gut involvement is common: Hashimoto's gastritis, celiac disease, and SIBO all co-occur at higher rates in Hashimoto's patients. For women with Hashimoto's and GI absorption problems, Tirosint has a pharmacokinetic advantage. For women with Hashimoto's who feel persistently symptomatic despite normal TSH, the Hoang et al. Data suggests NDT may improve wellbeing and cognitive symptoms.

PCOS

Thyroid disease and PCOS often co-exist. Thyroid dysfunction is found in up to 22.5% of women with PCOS, and thyroid antibody positivity is higher in PCOS than in the general population. Women with PCOS frequently have insulin resistance, which may worsen T4-to-T3 conversion. For PCOS women who feel unwell on levothyroxine alone, checking free T3 alongside TSH and free T4 is reasonable before deciding on a formulation switch.

Postpartum Thyroiditis

Women who develop hypothyroidism from postpartum thyroiditis often have transient disease. Levothyroxine (Tirosint or standard tablet) is typically started, and a trial off medication is offered after 12-18 months. NDT is not preferred for transient postpartum thyroiditis because the goal is to use the minimum effective intervention in a potentially self-limiting condition.

Celiac Disease and Malabsorption

Tirosint wins here. The gel capsule does not require acid dissolution, is absorbed in the proximal small bowel more completely than tablets, and has no excipients that provoke immune responses in celiac patients.

How to Switch Safely When One Fails

Switching from Armour Thyroid to Tirosint

1. Calculate the T4-equivalent dose: 1 grain Armour (60 mg) ≈ 100 mcg levothyroxine.
2. Start Tirosint at 80-90% of the calculated equivalent to avoid overtreatment in the transition.
3. Recheck TSH, free T4, and free T3 at 6 weeks. Adjust by 12.5-25 mcg increments.
4. Expect some symptom adjustment: loss of the T3 pulse can cause temporary fatigue or brain fog in the first 2-4 weeks.
5. If free T3 drops into low-normal and symptoms persist at 3 months, adding a small dose of liothyronine (5 mcg once or twice daily) may be preferable to returning to Armour.

Switching from Tirosint to Armour Thyroid

1. Calculate the NDT equivalent: 100 mcg levothyroxine ≈ 1 grain (60 mg) Armour.
2. Start at the calculated equivalent and recheck TSH at 6 weeks.
3. Free T3 and free T4 should both be checked at follow-up since the T4:T3 ratio in Armour differs from endogenous ratios.
4. Women with a history of atrial fibrillation, osteoporosis, or significant cardiovascular disease should discuss the added T3 load carefully with their clinician before switching.
5. Do not switch during pregnancy. Complete the pregnancy on T4-only therapy and reassess postpartum.

Who This Is Right For and Who Should Think Twice

Tirosint is the better starting point if you:

• Have documented GI absorption problems (celiac, SIBO, bariatric surgery, chronic PPI use)
• Are pregnant or planning pregnancy in the next 12 months
• Have cardiovascular disease or a history of atrial fibrillation (no T3 pulse)
• Have osteoporosis and need tight TSH control at a low-normal level
• Cannot tolerate lactose, acacia, or synthetic dyes in standard tablets

Armour Thyroid may be worth a trial if you:

• Have been on levothyroxine with normal TSH for at least 6 months but still feel hypothyroid
• Have low-normal free T3 despite adequate T4 dosing
• Have already tried dose optimization and T3 addition separately and found combination therapy more manageable in one pill
• Understand the fixed T4:T3 ratio limitation and accept monitoring every 3-6 months
• Are post-menopausal with stable cardiovascular health and normal bone density

Who should not switch to Armour without specialist input:

• Women who are pregnant or actively trying to conceive
• Women with a personal or family history of significant cardiac arrhythmia
• Women with documented osteoporosis or a T-score below minus 2.5 on DEXA
• Women with adrenal insufficiency (T3 can accelerate adrenal crisis in unrecognized adrenal fatigue)

The Evidence Gap: What We Still Do Not Know

Women have been underrepresented in thyroid trials for decades. The Hoang et al. 2013 trial enrolled 70 patients, which is small for the conclusions drawn. Long-term comparative data on bone outcomes, cardiovascular outcomes, and fertility-specific endpoints for NDT versus levothyroxine formulations in women across life stages does not exist at scale. Most of what clinicians apply to perimenopausal or postmenopausal thyroid management is extrapolated from younger populations or from general thyroid data not stratified by sex.

The Vita et al. 2014 absorption data for Tirosint, while compelling, was conducted primarily in patients with known absorption disorders; it is not clear that the advantage is equally meaningful in women without documented malabsorption. Clinicians and patients making decisions about formulation switches are doing so with the best available evidence, not definitive trial data. That is worth knowing.

Practical Monitoring Checklist After Any Formulation Switch

Check at 6 weeks after the switch, then every 3 months until stable:

| Lab | Why | |---|---| | TSH | Primary therapeutic target | | Free T4 | Confirms circulating T4 adequacy | | Free T3 | Particularly important after switching off NDT | | TPO antibodies (annually) | Tracks autoimmune activity in Hashimoto's | | Ferritin | Iron deficiency impairs T4-to-T3 conversion | | Fasting glucose and insulin | Relevant in PCOS; insulin resistance affects conversion | | DEXA (every 2 years on NDT) | Bone protection, especially post-menopause |

If TSH remains suppressed below 0.1 mIU/L at any stable dose, the dose is too high regardless of which formulation you are taking. Suppressed TSH is independently associated with atrial fibrillation and accelerated bone loss in post-menopausal women.